Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15005690 | 0.89 | L3MBTL1 (0.47) | L3MBTL1BRAFTP53LMNAMAPT | |
| SCHEMBL2479577 | 0.88 | L3MBTL1 (0.47) | L3MBTL1BRAFTP53LMNAMAPT | |
| SCHEMBL15005569 | 0.83 | L3MBTL1 (0.45) | L3MBTL1BRAFTP53LMNAMAPT | |
| SCHEMBL2477754 | 0.77 | SMN1; SMN2 (0.46) | L3MBTL1BRAFTP53MAPTCDC7 | |
| SCHEMBL2480456 | 0.77 | BRAF (0.53) | BRAFMAPTMAPK14 | |
| SCHEMBL2477136 | 0.77 | L3MBTL1 (0.48) | L3MBTL1BRAFTP53LMNAMAPT | |
| SCHEMBL2481763 | 0.74 | PDE4B (0.49) | LMNAMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL2477807 | 0.72 | LMNA (0.48) | L3MBTL1BRAFTP53LMNAMAPT | |
| SCHEMBL2477800 | 0.70 | LMNA (0.49) | L3MBTL1BRAFTP53LMNAMAPT | |
| SCHEMBL2481024 | 0.70 | LMNA (0.48) | L3MBTL1BRAFTP53LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| EP-2373664-B1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | disclosed |
| EP-2373664-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010070060-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K19, MAP4K3, MAP3K15 | L3MBTL1 3183/4885BRAF 41/4885TP53 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.